CSPC PHARMA (01093) · Company profile · Eqvero

CSPC PHARMA

01093HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	26.01 bn CNY	29.01 bn CNY	31.45 bn CNY	30.94 bn CNY	27.87 bn CNY
Cost of revenue	7.63 bn CNY	7.46 bn CNY	8.19 bn CNY	7.68 bn CNY	5.87 bn CNY
Research and development expense	5.9 bn CNY	5.28 bn CNY	4.87 bn CNY	4.03 bn CNY	3.44 bn CNY
Selling, general and administrative expense	7.29 bn CNY	9.74 bn CNY	10.33 bn CNY	11.51 bn CNY	11.45 bn CNY
Operating profit after depreciation	3.96 bn CNY	5.37 bn CNY	7.02 bn CNY	6.76 bn CNY	6.25 bn CNY
Operating profit before depreciation	5.28 bn CNY	6.61 bn CNY	8.1 bn CNY	7.76 bn CNY	7.11 bn CNY
EBIT	3.96 bn CNY	5.37 bn CNY	7.02 bn CNY	6.76 bn CNY	6.25 bn CNY
EBITDA	5.28 bn CNY	6.61 bn CNY	8.1 bn CNY	7.76 bn CNY	7.11 bn CNY
Interest expense	38.6 m CNY	43.67 m CNY	25.9 m CNY	24.89 m CNY	7.66 m CNY
Profit before tax	4.81 bn CNY	5.58 bn CNY	7.39 bn CNY	7.58 bn CNY	6.85 bn CNY
Income tax expense	931.73 m CNY	1.24 bn CNY	1.32 bn CNY	1.35 bn CNY	1.16 bn CNY
Income before extraordinary items	3.88 bn CNY	4.33 bn CNY	5.87 bn CNY	6.09 bn CNY	5.61 bn CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.